Week in Review: Sinopharm Transfers $4.6 Billion in Assets Including two COVID-19 Vaccines

Covid-19 Pandemic   Sinopharm, a China state-owned pharma, will transfer six vaccine companies that include two COVID-19 vaccines to Beijing Tiantan Biological, a listed company 50% owned by Sinopharm; the six companies are worth $4.6 billion;  Deals and Financings   Shanghai Ocumension Therapeutics acquired China rights to Alimera’s implant therapy for macular edema and other retina diseases in a $119 million agreement; StoneWise, a  Beijing  company offering AI-based small molecule drug development services, raised $100 million in Series B and B+ rounds; Shanghai BDgene completed a $9 million A round for its mRNA delivery platform, including a viroid-like particle delivery of CRISPR/Cas9 mRNA; Shanghai 's SciNeuro Pharma in-licensed Greater China rights to Lilly's alpha-synuclein targeted antibody therapies for Parkinson's Disease; Jilan's Qilu Pharma acquired  China  rights to a preclinical anti-MUC1 conjugate oncology drug from Peptron of South Korea;   Trials and Approvals   Shanghai Junshi Bio announced  China 's NMPA approved a third indication for the company's PD-1 drug in patients with urothelial carcinoma; Innovent Biologics of  Suzhou  reported positive data from a Phase III trial of its anti-PD-1 drug, Tyvyt® as a second line therapy for NSCLC; Adlai Nortye, a Hangzhou-New Jersey biopharma, dosed the first patient in a global Phase III trial of Buparlisib for head and neck squamous cell carcinoma; Gracell Biotech, a  Suzhou  cell therapy company, reported positive results from a China Phase I trial of its allogeneic CAR-T candidate; LintonPharm of Guangzhou was approved to start a China Phase I/II clinical trial of catumaxomab to treat bladder cancer; Suzhou Kintor Pharma will start  China  clinical trials of a proposed treatment for acne and androgenetic alopecia.   Stock Symbols: (HK: 1477) (NYSE: LLY) (KOSDAQ: 087010) (SHA: 600161) (HK: 1877; SHA: 688180) (HK: 01801) (NDQQ: GRCL) (HK: 9939) Share this with colleagues: // //